| Number of patients (%) | ||
| Concomitant drugs | Safety analysis population (n = 2602)a) | Efficacy analysis population (n = 1629) |
| At baseline | ||
| DPP-4 inhibitorsb) | 1342 (51.6) | 884 (54.3) |
| Sulfonylureas | 1460 (56.1) | 1142 (70.1) |
| Biguanides | 1101 (42.3) | 737 (45.2) |
| Thiazolidinediones | 327 (12.6) | 249 (15.3) |
| α-glucosidase inhibitors | 680 (26.1) | 433 (26.6) |
| Insulin secretagogues | 124 (4.8) | 74 (4.5) |
| During study period | ||
| DPP-4 inhibitorsb) | 1545 (59.4) | 988 (60.7) |
| Sulfonylureas | 1510 (58.0) | 1164 (71.5) |
| Biguanides | 1205 (46.3) | 792 (48.6) |
| Thiazolidinediones | 352 (13.5) | 269 (16.5) |
| α-glucosidase inhibitors | 780 (30.0) | 490 (30.1) |
| Insulin secretagogues | 178 (6.8) | 109 (6.7) |